Current and future therapeutical approaches for COVID-19

Drug Discov Today. 2020 Aug;25(8):1545-1552. doi: 10.1016/j.drudis.2020.06.018. Epub 2020 Jun 20.

¹ Henan Provincial Key Laboratory of Children's Genetics and Metabolic Diseases, Children's Hospital Affiliated to Zhengzhou University, Zhengzhou University, Zhengzhou 450001, China.
² School of Pharmaceutical Science, Zhengzhou University, Zhengzhou, Henan 450001, China.
³ Department of Endocrinology and Metabolism, Genetics, Children's Hospital Affiliated to Zhengzhou University, Zhengzhou University, Zhengzhou 450001, China.
⁴ Henan Provincial Key Laboratory of Children's Genetics and Metabolic Diseases, Children's Hospital Affiliated to Zhengzhou University, Zhengzhou University, Zhengzhou 450001, China; State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing 210093, China. Electronic address: zhuhl@nju.edu.cn.
⁵ School of Pharmaceutical Science, Zhengzhou University, Zhengzhou, Henan 450001, China. Electronic address: changjunbiao@zzu.edu.cn.

Abstract

We review the evolution of our clinical understanding of COVID-19, possible therapeutic targets, and prospects for COVID-19 management.